Press Releases

Date Title and Summary Additional Formats
Toggle Summary Retrophin to Present at Upcoming Investor Conferences
SAN DIEGO , Feb. 19, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Company management will present at the following upcoming investor conferences in February and March: 9th Annual SVB Leerink Global Healthcare Conference Date: Wednesday, February 26, 2020 Time: 9:30
View HTML
Toggle Summary Retrophin, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO , Feb. 13, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq: RTRX) today announced that on February 10, 2020 , the Compensation Committee of its Board of Directors granted inducement stock options to purchase an aggregate of 22,500 shares of its common stock to three new employees and
View HTML
Toggle Summary Retrophin to Report Fourth Quarter and Full Year 2019 Financial Results
SAN DIEGO , Feb. 10, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report fourth quarter and full year 2019 financial results on Monday, February 24, 2020 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss
View HTML
Toggle Summary Retrophin Provides Corporate Update and 2020 Outlook
SAN DIEGO , Jan. 13, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that, based on preliminary and unaudited financial data, the Company expects net product sales for the fourth quarter of 2019 to be approximately $47 million .
View HTML
Toggle Summary Retrophin to Present at the Jefferies 2019 London Healthcare Conference
SAN DIEGO , Nov. 14, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Eric Dube , Ph.D., chief executive officer, will present at the Jefferies 2019 London Healthcare Conference in London, UK on Thursday, November 21, 2019 at 12:40 p.m. GMT ( 7:40 a.m. ET ).
View HTML
Toggle Summary Retrophin Reports Third Quarter 2019 Financial Results
Enrollment on-track in pivotal Phase 3 clinical trials to support registration of sparsentan for patients with FSGS and IgAN Third quarter revenues rose nine percent to $44 million SAN DIEGO , Oct. 30, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today reported its third quarter 2019
View HTML
Toggle Summary Retrophin to Report Third Quarter 2019 Financial Results
SAN DIEGO , Oct. 16, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report third quarter 2019 financial results on Wednesday, October 30, 2019 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial
View HTML
Toggle Summary Retrophin Announces Presentation of Abstracts at ASN Kidney Week 2019
SAN DIEGO , Oct. 11, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that it will present new data from the Phase 2 DUET Study examining the impact of sparsentan on quality of life in focal segmental glomerulosclerosis (FSGS), at the American Society of Nephrology (ASN)
View HTML
Toggle Summary Retrophin Announces Appointment of Peter Heerma as Chief Commercial Officer
SAN DIEGO , Oct. 01, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced the appointment of Peter Heerma as chief commercial officer, effective immediately. In this newly created position, Mr. Heerma will be responsible for leading Retrophin’s commercial organization and
View HTML
Toggle Summary Retrophin to Present at the 2019 Cantor Global Healthcare Conference
SAN DIEGO , Sept. 26, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Eric Dube , Ph.D., chief executive officer, will present at the 2019 Cantor Global Healthcare Conference in New York City on Thursday, October 3, 2019 at 5:20 p.m. ET .
View HTML